Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMAB008 vs infliximab in rheumatoid arthritis (CTR20170934)
CTR20170934Phase 3Completed
- Sponsor
- Shanghai Biomabs
- Start
- Sep 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of infliximab-axxq in rheumatoid arthritis (RA), sponsored by Shanghai Biomabs. Started Sep 2017; status: completed.
02
Drugs
infliximab-axxq
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on CTR20170934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170934.